A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease

ID Number 14-1411

Principal Investigator(s)
Eliza B Geer

Department(s) or Division(s)
Neurosurgery

Description

The purpose of this study is to confirm the effectiveness and safety of LCI699 in treating patients with Cushing's disease.



Contact Information
Yelena Lalazar
(212) 241-2613
yelena.lalazar@mssm.edu

Recruiting Patients: Yes